The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Role of Transcription Factor Acetylation in Diabetic Kidney Disease
Open accessAbstract
Nuclear factor (NF)-κB and signal transducer and activator of transcription 3 (STAT3) play a critical role in diabetic nephropathy (DN). Sirtuin-1 (SIRT1) regulates transcriptional activation of target genes through protein deacetylation. Here, we determined the roles of Sirt1 and the effect of NF-κB (p65) and STAT3 acetylation in DN. We found that acetylation of p65 and STAT3 was increased in both mouse and human diabetic kidneys. In human podocytes, advanced glycation end products (AGEs) induced p65 and STAT3 acetylation and overexpression of acetylation-incompetent mutants of p65 and STAT3 abrogated AGE-induced expression of NF-κB and STAT3 target genes. Inhibition of AGE formation in db/db mice by pyridoxamine treatment attenuated proteinuria and podocyte injury, restored SIRT1 expression, and reduced p65 and STAT3 acetylation. Diabetic db/db mice with conditional deletion of SIRT1 in podocytes developed more proteinuria, kidney injury, and acetylation of p65 and STAT3 compared with db/db mice without SIRT1 deletion. Treatment of db/db mice with a bromodomain and extraterminal (BET)-specific bromodomain inhibitor (MS417) which blocks acetylation-mediated association of p65 and STAT3 with BET proteins, attenuated proteinuria, and kidney injury. Our findings strongly support a critical role for p65 and STAT3 acetylation in DN. Targeting protein acetylation could be a potential new therapy for DN.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Selective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262
Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase
Brunet, A., Sweeney, L. B., Sturgill, J. F., Chua, K. F., Greer, P. L., Lin, Y., Tran, H., Ross, S. E., Mostoslavsky, R., Cohen, H. Y., et al. (2004) · Science · doi:10.1126/science.1094637 · Cited by 3,239
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
Zuber, J., Shi, J., Wang, E., Rappaport, A. R., Herrmann, H., Sison, E. A., Magoon, D., Qi, J., Blatt, K., Wunderlich, M., et al. (2011) · Nature · doi:10.1038/nature10334 · Cited by 1,870
SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1
Pacholec, M., Bleasdale, J. E., Chrunyk, B., Cunningham, D., Flynn, D., Garofalo, R. S., Griffith, D., Griffor, M., Loulakis, P., Pabst, B., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.088682 · Cited by 915 · cited 2×
“Since there are currently no proven specific SIRT1 agonists (27,28), the development of other approaches to modulate TF acetylation is important.”
Resveratrol is not a direct activator of SIRT1 enzyme activity
Beher, D., Wu, J., Cumine, S., Kim, K. W., Lu, S., Atangan, L., & Wang, M. (2009) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2009.00901.x · Cited by 426
Sirt1 enhances skeletal muscle insulin sensitivity in mice during caloric restriction
Schenk, S., McCurdy, C. E., Philp, A., Chen, M. Z., Holliday, M. J., Bandyopadhyay, G. K., Osborn, O., Baar, K., & Olefsky, J. M. (2011) · Journal of Clinical Investigation · doi:10.1172/jci58554 · Cited by 197
Cited by
Sirtuins in Renal Health and Disease
Morigi, M., Perico, L., & Benigni, A. (2018) · Journal of the American Society of Nephrology · doi:10.1681/asn.2017111218 · Cited by 349
Pathogenic Pathways and Therapeutic Approaches Targeting Inflammation in Diabetic Nephropathy
Rayego-Mateos, S., Morgado-Pascual, J. L., Opazo-Ríos, L., Guerrero-Hue, M., García-Caballero, C., Vázquez-Carballo, C., Mas, S., Sanz, A. B., Herencia, C., Mezzano, S., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21113798 · Cited by 334
Diabetic nephropathy – is this an immune disorder?
Tesch, G. H. (2017) · Clinical Science · doi:10.1042/cs20160636 · Cited by 264
Guan, Y., Wang, S.-R., Huang, X.-Z., Xie, Q.-H., Xu, Y.-Y., Shang, D., & Hao, C.-M. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016040385 · Cited by 238
Increased podocyte Sirtuin-1 function attenuates diabetic kidney injury
Hong, Q., Zhang, L., Das, B., Li, Z., Liu, B., Cai, G., Chen, X., Chuang, P. Y., He, J. C., & Lee, K. (2018) · Kidney International · doi:10.1016/j.kint.2017.12.008 · Cited by 222
Self-citationImmune responses in diabetic nephropathy: Pathogenic mechanisms and therapeutic target
Chen, J., Liu, Q., He, J., & Li, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.958790 · Cited by 164
Novel Role of the SIRT1 in Endocrine and Metabolic Diseases
Lu, C., Zhao, H., Liu, Y., Yang, Z., Yao, H., Liu, T., Gou, T., Wang, L., Zhang, J., Tian, Y., et al. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.78654 · Cited by 160
Reduction in podocyte SIRT1 accelerates kidney injury in aging mice
Chuang, P. Y., Cai, W., Li, X., Fang, L., Xu, J., Yacoub, R., He, J. C., & Lee, K. (2017) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00255.2017 · Cited by 98
Self-citationNew progress in drugs treatment of diabetic kidney disease
Wang, J., Xiang, H., Lu, Y., Wu, T., & Ji, G. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111918 · Cited by 74
Podoplanin mediates the renoprotective effect of berberine on diabetic kidney disease in mice
Yu, J., Zong, G.-N., Wu, H., & Zhang, K.-Q. (2019) · Acta Pharmacologica Sinica · doi:10.1038/s41401-019-0263-3 · Cited by 27
Protective effect of EX-527 against high-fat diet-induced diabetic nephropathy in Zucker rats
Kundu, A., Richa, S., Dey, P., Kim, K. S., Son, J. Y., Kim, H. R., Lee, S.-Y., Lee, B.-H., Lee, K. Y., Kacew, S., et al. (2020) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2020.114899 · Cited by 27
NAD+ Anabolism Disturbance Causes Glomerular Mesangial Cell Injury in Diabetic Nephropathy
Li, X., Li, Y., Li, F., Chen, Q., Zhao, Z., Liu, X., Zhang, N., & Li, H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073458 · Cited by 13
Self-citation
Metadata
- Authors
- Liu, R., Zhong, Y., Li, X., Chen, H., Jim, B., Zhou, M.-M., Chuang, P. Y., & He, J. C.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2014-06-14
- Volume
- 63
- Issue
- 7
- Pages
- 2440-2453
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2099760082
- Cited by
- 216
- References
- 6
- FWCI
- 11.39
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.